On Tuesday, August 11, the president of Russia, Valdimir Putin, announced at a government meeting that his country had registered the first vaccine against the coronavirus. In the announcement, Putin himself announced that Sputnik V, as the product was named, is safe and “creates a stable immunity against the virus.”
At the time, the medical world received the announcement with skepticism, as Russia did not publish any study that fully supported the effectiveness of the product and that guaranteed that it had not skipped any of the phases of testing with humans.
Despite this, at the end of August the authorities announced the start of the last stage of clinical trials in 40,000 inhabitants of Moscow, the Russian capital.
On August 11, the Nikolai Gamaleya Center for Epidemiology and Microbiology officially registered the Russian vaccine Sputnik V, which will be produced in cooperation with the Russian Direct Investment Fund (RFPI).
(We recommend you read: The Colombian doctor working on a Russian vaccine trial against covid).
Although the results of these tests will be known in October or November, this Tuesday, September 15, the Russian Health Minister, Mikhail Murashko, revealed preliminary secondary symptoms in a sample of 300 volunteers.
“More than 300 people were vaccinated. About 14 percent of them complained of a slight weakness, mild muscle aches throughout the day, and sometimes fever“Murashko commented to the local press.
According to the minister, these effects are predictable reactions and are “just what is described in the instructions.”
In fact, it must be remembered that when the vaccine was announced Putin assured that he and his daughter had already tried it and that, in his case, both of the doses with which Sputnik V works had caused a temperature increase of up to 38 degrees.
“But then (that symptom) came to nothing and now he feels good,” the president said at the time.
The new announcement of the side effects contrasts with the study that was published in early August by the British medical journal ‘The Lancet’ and which indicated that Preliminary results from clinical trials of the vaccine had shown no adverse effects.
Despite the unwanted effects, Russia will continue with its plan to mass supply the vaccine to locals and foreigners after November.
Among the governments that showed their interest in acquiring the patent are those of Belarus, the Philippines, India, Brazil, Saudi Arabia, Mexico and Venezuela.
(We recommend you read: They reveal the manual for the use of the Russian vaccine against coronavirus).
For its part, the World Health Organization has said that there is “no magic formula against coronavirus” and, last Wednesday, September 9 lowered to 2022 the forecast on how long any vaccine could be available to the entire world population.
* With information from EFE